BioCryst Pharmaceuticals (NASDAQ:BCRX) reported its Q3 earnings results on Tuesday, November 1, 2022 at 07:00 AM.
Here’s what investors need to know about the announcement.
Earnings
BioCryst Pharmaceuticals beat estimated earnings by 17.86%, reporting an EPS of $-0.23 versus an estimate of $-0.28.
Revenue was up $34.83 million from the same period last year.
Past Earnings Performance
Last quarter the company beat on EPS by $0.02 which was followed by a 2.26% increase in the share price the next day.
Here’s a look at BioCryst Pharmaceuticals’s past performance:
| Quarter | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 |
|---|---|---|---|---|
| EPS Estimate | -0.34 | -0.37 | -0.3 | -0.29 |
| EPS Actual | -0.32 | -0.40 | -0.4 | -0.33 |
| Revenue Estimate | 64.31M | 51.36M | 50.56M | 39.38M |
| Revenue Actual | 65.53M | 49.92M | 47.16M | 40.99M |
To track all earnings releases for BioCryst Pharmaceuticals visit their earnings calendar here.
This article was generated by Benzinga’s automated content engine and reviewed by an editor.
